Peter Bross
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 2
- Oncology top 5%
- CAR-T cell therapy research 3
- Cancer Immunotherapy and Biomarkers 2
- Cancer Treatment and Pharmacology 2
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research 3
- Estrogen and related hormone effects 2
-
- Bladder and Urothelial Cancer Treatments 2
-
- Eosinophilic Disorders and Syndromes 2
- Co-authors
- Richard PazdurRobert C. KaneAnn T. FarrellAtiqur RahmanGang ChenGrant WilliamsEamon DuffySandip Kumar Roy
- Cited by
- HematologyOncologyGenetics
- Journals
- Clinical Cancer Research (2 papers)The Oncologist (2 papers)Journal of Clinical Oncology (1 paper)
- Partner nations
- United StatesThailand
In The Last Decade
Peter Bross
12 papers receiving 1.4k citations
Hit Papers
Peers
Comparison fields: 5 of 94
- Hematology 464
- Oncology 600
- Genetics 132
- Radiology, Nuclear Medicine and Imaging 279
- Molecular Biology 686
Countries citing papers authored by Peter Bross
This map shows the geographic impact of Peter Bross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Bross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Bross more than expected).
Fields of papers citing papers by Peter Bross
This network shows the impact of papers produced by Peter Bross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Bross. The network helps show where Peter Bross may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Peter Bross, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 8 | |
| 3 | 2023 | 0 | |
| 4 | 2019 | 0 | |
| 5 | 2014 | 4 | |
| 6 | 2013 | 17 | |
| 7 | 2008 | 12 | |
| 8 | Fulvestrant in postmenopausal women with advanced breast cancer. | 2003 | 46 |
| 9 | Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. | 2003 | 83 |
| 10 | Report from the FDA Approval Summary: Imatinib Mesylate Capsules for Treatment of Adult Patients with Newly Diagnosed Philadelphia Chromosome- positive Chronic Myelogenous Leukemia in Chronic Phase | 2003 | 1 |
| 11 | Velcade®: U.S. FDA Approval for the Treatment of Multiple Myeloma Progressing on Prior Therapybreakdown → | 2003 | 505 |
| 12 | 2002 | 62 | |
| 13 | Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.breakdown → | 2001 | 660 |
| 14 | 1999 | 5 |
About Peter Bross
Peter Bross is a scholar working on Hematology, Toxicology, Genetics, Oncology and Clinical Biochemistry, having authored 14 papers that have together received 1.4k indexed citations. Recurring topics across this work include CAR-T cell therapy research (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Bladder and Urothelial Cancer Treatments (2 papers), Eosinophilic Disorders and Syndromes (2 papers), Cancer Immunotherapy and Biomarkers (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Cancer Treatment and Pharmacology (2 papers) and Estrogen and related hormone effects (2 papers). The work is most often cited by research in Hematology (464 citations), Oncology (600 citations), Genetics (132 citations), Radiology, Nuclear Medicine and Imaging (279 citations) and Molecular Biology (686 citations). Peter Bross has collaborated with scholars based in United States and Thailand. Frequent co-authors include Richard Pazdur, Robert C. Kane, Ann T. Farrell, Atiqur Rahman, Gang Chen, Grant Williams, Eamon Duffy, Sandip Kumar Roy, R N Sridhara and Julie Beitz. Their work appears in journals such as Clinical Cancer Research, The Oncologist, Journal of Clinical Oncology, Pharmacogenomics and The American Journal of Gastroenterology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.